Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.30

-3.0%
HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$282.41M
EPS-2.2700
P/E Ratio-1.68
Earnings Date08/06/2026

lrmr

Income Tax Expense

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Competitors Analysis of Income Tax Expense

LRMR · NASDAQ
CompanyIncome Tax Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
168.00K
-68.2%N/AN/A
0.00
N/AN/AN/A
1.00K
0.0%N/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
144.00K
-53.2%N/A10.7%
468.00K
17.6%N/AN/A
0.00
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
637.00K
186.8%111.6%N/A
0.00
N/AN/AN/A
Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.3, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

Intrinsic Value
Current Price: $3.3